Biology subjects

Kote, S.

Publications and source records attributed to Kote, S..

7 recordsLinked to original sources

bioRxiv2026

STAT3 dual role in sex-biased and differentiation-gated interferon gamma memory

The innate immune system possesses a unique form of memory, known as trained immunity. An initial stimulus induces cellular reprogramming for a non-specific amplified response to a subsequent challenge. This process can be achieved through gene priming, where exposure to a specific cue sensitizes future gene expression. Interferon-gamma (IFN{gamma}) memory is a specialized form of priming, where both the initial and recall signals are mediated by the same IFN{gamma} cytokine. The mechanisms governing IFN{gamma} memory in humans remain poorly understood. We investigated the mechanisms governing IFN{gamma} memory and characterized it in human primary macrophages. We discovered a dual role for the STAT3 transcription factor in IFN{gamma} memory. It acts as a repressor of memory establishment by indirectly inhibiting STAT1 Ser727 phosphorylation, while also being required for memory recall. Furthermore, we demonstrated that IFN{gamma} memory is sex-biased, with males exhibiting a more pronounced effect characterized by reduced variability in gene expression upon re-exposure to IFN{gamma}. This defines IFN{gamma} recall as a function of transcriptional precision. We also identified a novel family of chemokine genes that exhibit IFN{gamma} concentration dependent memory effects. Additionally, we established a model system to study this process and found that memory is critically dependent on the cellular phenotype. Specifically, our results show that for some genes, monocyte-to-macrophage differentiation is necessary, while for others, this differentiation step is sufficient for recall of the previous response. Our findings redefine the IFN{gamma} memory program, establishing it as a sex-biased phenomenon governed by a novel regulatory network involving differentiation and STAT3 function. These insights provide critical context for understanding immune heterogeneity and are essential for the rational design of personalized therapies that harness trained immunity.

molecular biology↗

bioRxiv2026

Novel native serum peptidomics workflow enables the discovery of circulating subtype-specific peptide biomarkers in acute ischemic and haemorrhagic stroke

Novel serum peptidomics offers a direct insight into proteolytic activity, tissue injury, and systemic signaling. Nevertheless, existing workflows suffer from low peptide yields, low throughput, and limited recovery of low-abundance species. Here we present a native serum peptidomics protocol that integrates mild acid treatment, solid-phase extraction with molecular weight cutoff filtration and data-independent acquisition mass spectrometry (DIA-MS). The protocol requires less than 100 {micro}l of serum or plasma, is completed within hours, time-cost-effective and compatible with 96-well formats without specialized equipment. Applied to a proof-of-concept cohort of patients with acute ischemic stroke (AIS), intracranial haemorrhage (ICH), and healthy controls, the workflow identified over 12,000 peptides, exceeding the three-fold threshold of existing peptidomics approaches. DIA-MS analysis across independent batches demonstrated 78-83% peptide overlap and consistent fold-change directionality. We further introduce peptide locus analysis, which aggregates overlapping peptides within defined protein regions. This approach revealed bidirectional regulation within individual precursor proteins such as the fibrinogen alpha chain (FIBA), resolving intraprotein proteolytic dynamics. Three candidate peptides from TYB4, CO4B, and ITIH4 proteins accurately distinguished stroke subtypes and controls, while characteristic shifts in peptide physicochemical properties were observed across strokes. This workflow substantially advances the sensitivity, throughput, and biological resolution of serum peptidomics for quantitative multi-biomarker discovery, validation and its output promises effective implementation of AI/ML models aiming for new dimensions in diagnostics, prognostics, prediction and monitoring.

neuroscience↗

bioRxiv2026

Benchmarking five extracellular vesicle proteomics workflows, including low-input Exo-insert and Exo-SP3, for deep mass spectrometry profiling

Small extracellular vesicles (sEVs) are key mediators of intercellular communication, influencing diverse pathological processes, including cancer. While mass spectrometry (MS) has enabled the proteomic analysis of sEVs, sample preparation losses remain a critical bottleneck, particularly for scarce tissue-derived sEVs (Ti-EVs). Here, we systematically benchmark five proteomic workflows introducing Exo-insert, a novel single-vessel method, and Exo-SP3, across both Ti-Evs and cell culture-derived sEVs (CCM-EVs) at low input (0.5-4 {micro}g). Exo-insert and Exo-SP3 enable the identification of [~]1100 protein groups from as little as 0.5 {micro}g sEV input. Notably, optimal sample preparation for MS is source-dependent: Exo-insert and Exo-SP3 display divergent performance across sEV sources. Comparative DDA/DIA analyses establish sample preparation as the primary determinant of proteome recovery, offering a practical framework that matches workflows to sEV amounts and source-specific content for biomarker discovery.

cancer biology↗

bioRxiv2026

Mature tumoroids recapitulate clinically relevant drug response through extended 3D culture in PDAC

BackgroundDrug responses in pancreatic ductal adenocarcinoma (PDAC) vary sharply across in vitro culture formats, but most 2D-3D comparisons conflate microenvironmental cues with time-dependent cellular adaptation. As a result, conventional assays frequently overestimate drug efficacy and poorly reflect clinical pharmacology. Main findingsWe profiled MiaPaCa-2, PANC-1, and CFPAC-1 grown in an extracellular-matrix (ECM) hydrogel for 1-12 days, defining extended 3D cultures ([≥]10 days) as mature tumoroids, and quantified 72 h drug responses to a multi-class oncology panel using growth-rate (GR) metrics to normalize for proliferation across formats and durations. Prolonged 3D pre-culture induced broad tolerance, with typical 10-100x reductions in sensitivity to standards of care (5-fluorouracil, SN38, oxaliplatin, gemcitabine, paclitaxel), following a reproducible susceptibility hierarchy (MiaPaCa-2 > PANC-1 > CFPAC-1) after GR correction. In mature tumoroids, GR values closely approximated clinically observed plasma exposures (e.g., within <4x for 5-FU and <0.5x for gemcitabine), whereas 2D and short-term organoid assays markedly underestimated resistance, often by >100x, thereby overstating drug activity. Notably, CFPAC-1 exhibited increased sensitivity to SN38 and trametinib under mature-organoid conditions, demonstrating that microenvironmental conditioning can invert responses for selected mechanisms. Transcriptomic profiling revealed coordinated up-regulation of multiple ABC transporters with extended 3D residence, tracking resistance phenotypes across lines and implicating transporter-linked tolerance programs. SignificanceTogether, these data identify time-in-3D and the emergence of mature tumoroids as dominant, previously under-controlled determinants of PDAC pharmacology that both induce tolerance and unmask context-dependent vulnerabilities. We propose incorporating both short-term and mature-tumoroid screening arms into preclinical workflows, reporting pre-culture duration alongside GR-normalized effect sizes, and leveraging transporter-informed biomarkers to guide regimen prioritization and sequencing. This framework enhances physiological relevance, reproducibility, and translational fidelity in PDAC drug discovery.

cancer biology↗

bioRxiv2024

Universal toolset for mass spectrometric analysis of intracellular peptidome and small protein fraction

The analysis of native intracellular peptidome has gained significant attention in recent years. However, there is still a need for more knowledge regarding various sample preparation methods that facilitate efficient and reproducible recovery of peptides, which can then be analyzed using quantitative liquid chromatography-mass spectrometry. A similar situation exists in small proteome research, typically defined as polypeptides with masses of less than 100 amino acids, often too long for easy identification without enzymatic digestion. In this context, we describe a set of methods that involve simple denaturation and solid-phase extraction of polypeptides, applicable for isolating short intracellular polypeptides within the desired length range. Our work demonstrates the efficiency and reproducibility of these methods for quantitative analysis of the peptidome in mammalian cells. Additionally, we investigated the flexibility of adjusting the mass range through ultrafiltration. We have shown that these methods can be adapted for highly efficient enrichment and fractionation of small proteins, resulting in polypeptide isolates suitable for tryptic digestion and intact protein analysis. Moreover, we describe the use of freely available computational tools that can effectively manage the analysis of the resulting data. The research presented here will benefit the global scientific community in both fundamental (protein turnover, proteolytic processing, non-canonical open reading frames, etc.) and applied sciences (bioactive/neuro peptide discovery, precision medicine, vaccines, etc.), and other areas that could benefit from selective analysis of short native polypeptides.

cancer biology↗

bioRxiv2022

SRSF1 as a novel interacting partner for IFITM1/3 unravels the emergent role of IFITM1/3 mediating protein expression

IFITM proteins play a role in cancer cell progression through undefined mechanisms. Here, we propose an emergent role of IFITM1/3 regulating protein synthesis. SBP-tagged IFITM1 protein was used to identify an association of IFITM1 protein with the cytosolic isoform of SRSF1 that transports mRNA to the ribosome. This cytosolic association was confirmed in situ using proximity ligation assays for SRSF1 and IFITM1/3, suggesting a role associated with translation. Accordingly, IFITM1/3 were shown to interact with HLA-B mRNA in response to IFN{gamma} stimulation using RNA-protein proximity ligation assays. In addition, shotgun RNA sequencing in IFITM1/IFITM3 null cells and wt-SiHa cells indicated that reduced HLA-B gene expression does not account for lowered HLA-B protein synthesis in response to IFN{gamma}. Furthermore, ribosome profiling using sucrose gradient sedimentation identified a reduction in 80S ribosomal fraction an IFITM1/IFITM3 null cells compared to their wild-type counterpart, partially reverted by IFITM1/3 complementation. Our data all together link the binding of IFITM1/3 proteins to HLA-B mRNA and SRSF1 as a mechanism to catalyze the synthesis of target proteins, suggesting an RNA chaperonin role for IFITM1/3 proteins. SignificanceIFITMs are widely studied for their role in inhibiting viruses, and multiple studies have associated IFITMs with cancer progression. However, mechanistic insights are not well understood. Our study proposes that IFITMs have a role regulating protein synthesis, a pivotal function highly relevant for viral infection and cancer progression. Our results suggest that IFITM1/3 is present in the ribosomal fraction and regulates particular protein expression; among them, we identified HLA-B. Changes in HLA-B expression could impact the presentation and recognition of oncogenic antigens on the cell surface by cytotoxic T cells and, ultimately, limit tumor cell eradication. In addition, the role of IFITMs mediating protein translation is relevant, as has the potential of regulating the expression of viral and oncogenic proteins.

cancer biology↗

bioRxiv2022

A comprehensive library of canonical and non-canonical MHC class I antigens for cancer vaccine development.

A longstanding disconnect between the growing number of MHC Class I immunopeptidomic studies and genomic medicine hinders cancer vaccine design. We develop COD-dipp to genomically map the full spectrum of detected canonical and non-canonical (non-exonic) MHC Class I antigens from 26 cancer studies. We demonstrate that patient mutations in regions overlapping physically identified antigens better predict immunotherapy response when compared to neoantigen predictions. We suggest a vaccine design approach using 140,966 highly immune-visible regions of the genome annotated by their expression and haplotype frequency in the human population. These regions tend to be highly conserved, mutated in cancer and harbor 7.8 times more immunogenicity. Intersecting pan-cancer mutations with these immune surveilled regions revealed a potential to create off-the-shelf multi-epitope vaccines against public neoantigens. Here we release COD-dipp, a cancer vaccine toolkit as a web-application (https://www.proteogenomics.ca/COD-dipp) and open-source high-throughput resource.

bioinformatics↗